Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors

Theranostics

Volumn 5, Issue 10, 2015, Pages 1154-1165

  Geng, Lingling ^a   Wang, Zihua ^a   Yang, Xiaoliang ^a   Li, Dan ^a   Lian, Wenxi ^a   Xiang, Zhichu ^a   Wang, Weizhi ^a   Bu, Xiangli ^a   Lai, Wenjia ^a   Hu, Zhiyuan ^a   Fang, Qiaojun ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

breast cancer; HER2 targeted peptide; MD simulation; structure based design

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEPTIDE 23; PEPTIDE 26; PEPTIDE 27; PEPTIDE 27 24M; PEPTIDE 32; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; PEPTIDE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; EX VIVO STUDY; FEMALE; HER2 POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; IMMUNOHISTOCHEMISTRY; KINETICS; METABOLISM; NEOPLASM; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2;

EID: 84945898755     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.12398     Document Type: Article

References (56)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-37.
2. Burgess AW, Cho H-S, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, et al. An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Mol Cell. 2003; 12: 541-52.
3. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003; 284: 99-110.
4. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37 (Suppl 4): S3-S8.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-82.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
7. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993; 11: 1936-42.
8. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer. J Clin Oncol. 2006; 24: 5658-63.
9. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89: 4285-9.
10. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006; 232: 123-38.
11. Tolaney S. New HER2-positive targeting agents in clinical practice. Curr Oncol Rep. 2014; 16: 013-0359.
12. Schroeder RL, Stevens CL, Sridhar J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules. 2014; 19: 15196-212.
13. Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E, et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987; 1: 107-13.
14. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res. 2008; 14: 3840-9.
15. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007; 67: 2773-82.
16. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A. 2010; 107: 15039-44.
17. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421: 756-60.
18. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5: 317-28.
19. Ekerljung L, Lindborg M, Gedda L, Frejd FY, Carlsson J, Lennartsson J. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Biophys Res Commun. 2008; 377: 489-94.
20. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010; 51: 892-7.
21. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel. 2004; 17: 455-62.
22. Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging. 2006; 33: 631-8.
23. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Hoiden-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66: 4339-48.
24. Wang J, Hou T, Xu X. Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models. Curr Comput Aided Drug Des. 2006; 2: 287-306.
25. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models. Acc Chem Res. 2000; 33: 889-97.
26. Homeyer N, Gohlke H. Free Energy Calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area Method. Mol Inf. 2012; 31: 114-22.
27. Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol. 2003; 330: 891-913.
28. Hou T, Xu Z, Zhang W, McLaughlin WA, Case DA, Xu Y, et al. Characterization of domain-peptide interaction interface: a generic structure-based model to decipher the binding specificity of SH3 domains. Mol Cell Proteomics. 2009; 8: 639-49.
29. Hou T, Zhang W, Case DA, Wang W. Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. J Mol Biol. 2008; 376: 1201-14.
30. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23: 2947-8.
31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28: 235-42.
32. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem. 2003; 24: 1999-2012.
33. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983; 79: 926-35.
34. Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977; 23: 327-41.
35. Darden T, York D, Pedersen L. Particle mesh Ewald: An N [center-dot] log(N) method for Ewald sums in large systems. J Chem Phys. 1993; 98: 10089-92.
36. Tsui V, Case DA. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers. 2000; 56: 275-91.
37. Weiser Jr, Shenkin PS, Still WC. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem. 1999: 217-30.
38. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, Merz KM, Jr., et al. The Amber biomolecular simulation programs. J Comput Chem. 2005; 26: 1668-88.
39. Sun H, Li Y, Shen M, Tian S, Xu L, Pan P, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Phys Chem Chem Phys. 2014; 16: 22035-45.
40. Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model. 2011; 51: 69-82.
41. Cui W, Cheng YH, Geng LL, Liang DS, Hou TJ, Ji MJ. Unraveling the allosteric inhibition mechanism of PTP1B by free energy calculation based on umbrella sampling. J Chem Inf Model. 2013; 53: 1157-67.
42. Hou T, Yu R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. J Med Chem. 2007; 50: 1177-88.
43. Geng L, Gao J, Cui W, Tang Y, Ji M, Chen B. Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases. J Comput Aided Mol Des. 2012; 26: 1327-42.
44. Gohlke H, Kiel C, Case DA. Insights into Protein-Protein Binding by Binding Free Energy Calculation and Free Energy Decomposition for the Ras-Raf and Ras-RalGDS Complexes. J Mol Biol. 2003; 330: 891-913.
45. Onufriev A, Bashford D, Case DA. Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins. 2004; 55: 383-94.
46. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10: 515-27.
47. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer. 2010; 4: 35-41.
48. Zheng D, Aramini JM, Montelione GT. Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data. Protein Sci. 2004; 13: 549-54.
49. Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.3r1. 2010.
50. Zhu L, Wang K, Cui J, Liu H, Bu X, Ma H, et al. Label-free quantitative detection of tumor-derived exosomes through surface plasmon resonance imaging. Anal Chem. 2014; 86: 8857-64.
51. Gorodkiewicz E, Guszcz T, Roszkowska-Jakimiec W, Kozlowski R. Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging. Oncol Lett. 2014; 8: 1323-7.
52. Villiers MB, Cortay JC, Cortes S, Bloquel B, Brichler S, Brakha C, et al. Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging. J Clin Microbiol. 2015; 53: 1164-71.
53. Wang W, Zhang D, Wei Z, Wang Z, Bu X, Yang S, et al. Label-free detection microarray for novel peptide ligands screening base on MS-SPRi combination. Talanta. 2015; 134: 705-11.
54. Wang W, Wei Z, Zhang D, Ma H, Wang Z, Bu X, et al. Rapid screening of peptide probes through in situ single-bead sequencing microarray. Anal Chem. 2014; 86: 11854-9.
55. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm. 2005; 20: 239-48.
56. Hue JJ, Lee HJ, Jon S, Nam SY, Yun YW, Kim JS, et al. Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice. J Vet Sci. 2013; 14: 473-9.